Compare Novo Nordisk A/S (NVO) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Novo Nordisk A/S trades at $45.8 (market cap $207.85B), while Direxion Daily S&P 500 Bull 3X Shares trades at $296.64. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SPXL | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $296.39 |
52-Week Low | $35.29 | $170.20 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
SPXL trades at $295.39, down 0.27% in the last session, with technical indicators showing a bullish trend from moving averages but overbought signals from RSI levels above 70. The stock's pivot point at $294 and resistance at $296 suggest near-term price sensitivity. Recent news highlights S&P 500 record highs and AI-driven earnings optimism, though valuation concerns persist.
Outlook remains cautiously optimistic amid strong market momentum, with opportunities from AI growth and corporate earnings, but risks include high valuations and potential pullbacks. Investors should balance bullish technicals with fundamental prudence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
